AU5687198A - Method for treating multiple sclerosis - Google Patents

Method for treating multiple sclerosis

Info

Publication number
AU5687198A
AU5687198A AU56871/98A AU5687198A AU5687198A AU 5687198 A AU5687198 A AU 5687198A AU 56871/98 A AU56871/98 A AU 56871/98A AU 5687198 A AU5687198 A AU 5687198A AU 5687198 A AU5687198 A AU 5687198A
Authority
AU
Australia
Prior art keywords
amino
pyrimidinol
bromo
iodo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56871/98A
Other languages
English (en)
Inventor
Stephen E. Buxser
Francis A. Fitzpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AU5687198A publication Critical patent/AU5687198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU56871/98A 1996-12-12 1997-12-03 Method for treating multiple sclerosis Abandoned AU5687198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3264896P 1996-12-12 1996-12-12
US60032648 1996-12-12
PCT/US1997/021402 WO1998025596A2 (fr) 1996-12-12 1997-12-03 Methode de traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
AU5687198A true AU5687198A (en) 1998-07-03

Family

ID=21866063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56871/98A Abandoned AU5687198A (en) 1996-12-12 1997-12-03 Method for treating multiple sclerosis

Country Status (5)

Country Link
EP (1) EP0948331A2 (fr)
JP (1) JP2001505911A (fr)
AU (1) AU5687198A (fr)
CA (1) CA2269681A1 (fr)
WO (1) WO1998025596A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
EP1144390A2 (fr) * 1999-01-22 2001-10-17 Amgen Inc., Inhibiteurs de kinase
WO2001068613A1 (fr) * 2000-03-17 2001-09-20 Nissan Chemical Industries, Ltd. Dérivés pyrimidinone et herbicides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434157A (en) * 1979-03-19 1995-07-18 The Upjohn Company 6-aryl pyrimidine compounds and method for treating viral infections and inducing interferon production
DE3008693A1 (de) * 1979-03-19 1980-10-02 Upjohn Co 6-aryl-pyrimidinverbindungen
AU7798994A (en) * 1993-10-20 1995-05-08 Upjohn Company, The Pyrimidinones as antiarthritic and anti-inflammatories

Also Published As

Publication number Publication date
CA2269681A1 (fr) 1998-06-18
WO1998025596A3 (fr) 1998-08-13
EP0948331A2 (fr) 1999-10-13
WO1998025596A2 (fr) 1998-06-18
JP2001505911A (ja) 2001-05-08

Similar Documents

Publication Publication Date Title
DE69328558T2 (de) Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
EP0468520A2 (fr) Remèdes immunostimulants contenant des séquences d'ADN palindromique
WO2007065167A1 (fr) Utilisation de doses elevees de medicaments comprenant de l'oxazaphosphorine pour le traitement de troubles immunitaires
STRINGFELLOW et al. Interferon induction by 5-halo-6-phenyl pyrimidinones
US5716959A (en) Method of treating disease with piperazine zwitterion compounds
NL8301913A (nl) Middel voor het versterken van de antitumor activiteit van een middel tegen tumoren.
JP3496937B2 (ja) コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
EP0225759B1 (fr) Compositions d'interféron
AU5687198A (en) Method for treating multiple sclerosis
WO2002085916A1 (fr) 9-[(5-dihydroxyboryl)-pentyl]purines, inhibiteur de cytokines inflammatoires
EP0167936A2 (fr) Utilisation d'actinonine comme immunopotentiateur
JP2823453B2 (ja) インターロイキン−６の医薬組成物
Lefkowitz et al. Cocaine reduces macrophage killing by inhibiting reactive nitrogen intermediates
US5264208A (en) Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent
CN115645385B (zh) 甘草查尔酮b在制备治疗和/或预防ⅰ型干扰素病药物中的应用
US5059418A (en) Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
EP0290817A2 (fr) Utilisation d'oxétanocine pour inhiber HIV
JPS6193130A (ja) 低投与量にてヒトの各種病気を系統的に処置するためのγ‐インタフエロン含有剤
JP3816522B2 (ja) 造血機能に関して刺激活性を示すｍｄｐ誘導体および複合体ならびにそれらを含む組成物
AU611577B2 (en) Use of ubenimex for treating myelodysplastic syndrome
Cerruti et al. Synergistic interaction between interferon-α and acyclovir in the treatment of herpes simplex virus type 1 infection in mice
EP1250147B1 (fr) Utilisation de l'interferon-alpha dans le traitement le traitement du sarcome de ewing
DE3872749T2 (de) Anwendung von odc-inhibitoren, dacarbazin und interferon in der behandlung boesartiger melanome.
JP2003137784A (ja) インターフェロンγ産生促進剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted